Genes (21)
Species: human : 21 | |
Human | PROM2 | 150696 | prominin 2 | The PROM2 gene was shown to effectively separate these two tumor(chromophobe renal cell carcinoma (RCC) and benign oncocytoma) groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues | Human | MAL2 | 114569 | mal, T-cell differentiation protein 2 (gene/pseudogene) | The MAL2 gene was shown to effectively separate these two tumor(chromophobe renal cell carcinoma (RCC) and benign oncocytoma) groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues | Human | ESRP1 | 54845 | epithelial splicing regulatory protein 1 | The FLJ20171 gene was shown to effectively separate these two chromophobe renal cell carcinoma (RCC) and benign oncocytoma groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues | Human | ANKRD2 | 26287 | ankyrin repeat domain 2 (stretch responsive muscle) | ARPP was localized in mitochondria and nuclei in both the normal distal renal tubule and oncocytoma but not in chromophobe renal cell carcinomas | Human | MAD2L2 | 10459 | MAD2 mitotic arrest deficient-like 2 (yeast) | Chromophobe renal cell carcinoma presented underexpression of MAD1, and MAD2L2 | Human | AP1M2 | 10053 | adaptor-related protein complex 1, mu 2 subunit | The AP1M2 gene was shown to effectively separate these two tumor(chromophobe renal cell carcinoma (RCC) and benign oncocytoma) groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues | Human | CLDN8 | 9073 | claudin 8 | claudin-7 and claudin-8 have potential use as immunohistochemical biomarkers in the differential diagnosis of chromophobe renal cell carcinoma and oncocytoma | Human | S100A1 | 6271 | S100 calcium binding protein A1 | S100A1 immunodetection is potentially useful for the differential diagnosis between chromophobe renal cell carcinoma and oncocytoma | Human | RARB | 5915 | retinoic acid receptor, beta | Study demonstrate for the first time a significant and specific overexpression of RAR-beta(1) in chromophobe renal cell carcinoma | Human | PXN | 5829 | paxillin | expression in conventional renal cell carcinomas (RCCs), papillary RCCs, chromophobe RCCs, collecting duct carcinomas, oncocytomas; role in signal transductions as a focal adhesion between tumor cells and the ECM in tumors with collecting duct phenotypes | Human | PRSS8 | 5652 | protease, serine, 8 | The PRSS8 gene was shown to effectively separate these two tumor(chromophobe renal cell carcinoma (RCC) and benign oncocytoma) groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues | Human | PAX2 | 5076 | paired box 2 | Immunohistochemical Analysis for Cytokeratin 7, KIT, and PAX2: Value in the Differential Diagnosis of Chromophobe Cell Carcinoma. Immunohistochemistry for aquaporin-1, aquaporin-2, PAX-2, CD10, and cytokeratin 7 was performed on 102 clear cell renal cell carcinomas, 44 papillary renal cell carcinomas (among them 34 type 1 and 10 type 2), 24 chromophobe renal cell carcinomas, three collecting duct carcinomas (carcinomas of the collecting ducts of Bellini), and 29 oncocytomas. PAX-2 and CD10 was found in the majority of clear cell renal cell carcinomas (88 and 85%, respectively) but only in few papillary renal cell carcinomas, chromophobe renal cell carcinomas and oncocytomas. Immunohistochemistry for aquaporin-1, aquaporin-2, PAX-2, CD10, and cytokeratin 7 was performed on 102 clear cell renal cell carcinomas, 44 papillary renal cell carcinomas (among them 34 type 1 and 10 type 2), 24 chromophobe renal cell carcinomas, three collecting duct carcinomas (carcinomas of the collecting ducts of Bellini), and 29 oncocytomas. PAX-2 and CD10 was found in the majority of clear cell renal cell carcinomas (88 and 85%, respectively) but only in few papillary renal cell carcinomas, chromophobe renal cell carcinomas and oncocytomas. | Human | MST1R | 4486 | macrophage stimulating 1 receptor (c-met-related tyrosine kinase) | Expression of RON Proto-oncogene in Renal Oncocytoma and Chromophobe Renal Cell Carcinoma. To determine its diagnostic value, we studied Ron protein expression by immunohistochemistry in a larger number of renal cell neoplasms with emphasis on chromophobe renal cell carcinomas. Ninety-nine percent of oncocytomas (69 of 70) and 96% of chromophobe renal cell carcinomas (55 of 57) showed moderate to strong, diffuse cytoplasmic Ron immunoreactivity with intensities > or =2, while only 17% of other renal cell carcinoma subtypes stained with intensities > or =2. Our study indicates that Ron immunostaining cannot be used to distinguish oncocytoma from chromophobe renal cell carcinoma. The above results demonstrate that: 1) KIT is a very sensitive marker for both chromophobe renal cell carcinoma and renal oncocytoma; 2) immunohistochemistry using antibodies to KIT combined with RCC was sufficient to discriminate between chromophobe renal cell carcinoma and the granular cell variant of clear cell renal cell carcinoma; and 3) neither RON, nor KIT, nor a combination of this panel can be used to distinguish chromophobe renal cell carcinoma from renal oncocytoma. RON was 100% positive in the chromophobe renal cell carcinomas (11 of 11) and renal oncocytomas (12 of 12) but only 50% positive in the granular cell variant of clear cell renal cell carcinoma (3 of 6). Recently, it was reported that RON proto-oncogene, encoding a receptor tyrosine kinase, was strongly expressed in renal oncocytomas but not in any renal cell carcinomas, including 5 chromophobe renal cell carcinomas, which morphologically resemble oncocytomas. We investigated the expression of Ron, Ki-67 (proliferation index), p53, and bcl-2 (proapoptotic and antiapoptotic proteins, respectively) in 50 renal tumors (19 clear cell carcinomas, 18 oncocytomas, 7 papillary cell carcinomas, 5 chromophobe cell carcinomas, and 1 carcinoma with sarcomatoid areas). | Human | NR3C2 | 4306 | nuclear receptor subfamily 3, group C, member 2 | Our study indicates MR and 11beta-HSD2 are both sensitive and specific markers of the distal nephron and its related neoplasms (chromophobe renal cell carcinomas and oncocytomas) | Human | KITLG | 4254 | KIT ligand | KIT expression is a hallmark of oncocytoma and chromophobe renal cell carcinoma | Human | KRT7 | 3855 | keratin 7 | Cytokeratin 7 was found in the majority of type 1 papillary renal cell carcinomas and chromophobe renal cell carcinomas | Human | KIT | 3815 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | KIT could be a useful marker for chromophobe renal cell carcinomas found a significant elevation of c-kit protein messenger RNA and protein overexpression not only in chromophobe renal cell carcinomas but also in oncocytomas Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. | Human | CLDN7 | 1366 | claudin 7 | Claudin-7 to be a candidate expression marker for distinguishing chromophobe renal cell carcinoma from other renal tumor subtypes, including the morphologically similar oncocytoma claudin-7 and claudin-8 have potential use as immunohistochemical biomarkers in the differential diagnosis of chromophobe renal cell carcinoma and oncocytoma | Human | CDH16 | 1014 | cadherin 16, KSP-cadherin | Expression of kidney-specific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma. We found that chromophobe renal cell carcinomas consistently (96.7% of cases) demonstrated a distinctive membrane pattern of Ksp-cadherin expression, whereas renal oncocytomas (3.2%), clear cell renal cell carcinomas (0%), papillary renal cell carcinomas (2.2%), and collecting duct carcinomas (0%) usually did not express Ksp-cadherin. We compared Ksp-cadherin expression in 212 renal tumors, including 102 clear cell renal carcinomas, 46 papillary renal cell carcinomas, 30 chromophobe carcinomas, 3 collecting duct carcinomas, and 31 oncocytomas. Immunohistochemical analysis of Ksp-cadherin offers a fast, reliable approach for the distinguishing between renal oncocytoma and chromophobe renal cell carcinoma that is applicable for routine pathology laboratory studies without the need for time-consuming and costly ancillary studies. Ksp-cad is a useful tumor type associated marker for distinguishing chromophobe renal cell carcinoma and renal oncocytoma from the wide range of nonintercalated cell-related adult renal epithelial neoplasms Whereas CK7 was detected in different types of renal cell carcinomas, Ksp-cadherin was expressed almost exclusively in chromophobe renal cell carcinomas. | Human | CD3E | 916 | CD3e molecule, epsilon (CD3-TCR complex) | CD3 expression was strong in normal proximal and distal tubular epithelium and in renal oncocytomas, weak in chromophobe carcinoma, and negative in clear cell carcinomas, in papillary renal cell carcinoma, and in a transitional cell carcinoma | Human | BRAF | 673 | v-raf murine sarcoma viral oncogene homolog B | We have analyzed the BRAF locus on chromosome 7q34 with microsatellites for allelic changes and exons 11 and 15 of the BRAF with sequencing for mutations in 50 kidney cancers including 20 papillary, 15 conventional and 15 chromophobe renal cell carcinomas (RCC). |
|